Intake of coffee, caffeine and other methylxanthines and risk of Type I vs Type II endometrial cancer

BACKGROUND: Coffee and other sources of methylxanthines and risk of Type I vs Type II endometrial cancer (EC) have not been evaluated previously. METHODS: Prospective cohort of 23 356 postmenopausal women with 471 Type I and 71 Type II EC cases. RESULTS: Type I EC was statistically significantly ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Uccella, S, Mariani, A, Wang, A H, Vierkant, R A, Cliby, W A, Robien, K, Anderson, K E, Cerhan, J R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790186/
https://www.ncbi.nlm.nih.gov/pubmed/24022184
http://dx.doi.org/10.1038/bjc.2013.540
Descripción
Sumario:BACKGROUND: Coffee and other sources of methylxanthines and risk of Type I vs Type II endometrial cancer (EC) have not been evaluated previously. METHODS: Prospective cohort of 23 356 postmenopausal women with 471 Type I and 71 Type II EC cases. RESULTS: Type I EC was statistically significantly associated with caffeinated (relative risk (RR)=0.65 for 4+ cups per day vs ⩽1 cup per month: 95% confidence interval (CI): 0.47–0.89) but not decaffeinated (RR=0.76; 95% CI: 0.50–1.15) coffee intake; there were no associations with tea, cola or chocolate, or for Type II EC. The inverse association with caffeinated coffee intake was specific to women with a body mass index 30+ kg m(−2) (RR=0.56; 95% CI: 0.36–0.89). CONCLUSION: Coffee may protect against Type I EC in obese postmenopausal women.

Ejemplares similares